Strong dollar plus strong franc equals worries for global Big Pharma
22 January 2015
When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche ($RHHBY) and Novartis ($NVS). And now, Johnson & Johnson's ($JNJ) fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.
India opens medical device industry to foreign direct investment
21 January 2015
India's medical device industry will officially open Jan. 21 to unlimited foreign direct investment (FDI) as the government kicks off what is expected to be a year of vast changes in the way it regulates the products.
Health IT VC funding more than doubles in 2014
21 January 2015
Healthcare technology had a great year for venture capital funding in 2014, raking in more than double the amount it did a year prior, according to a Mercom Capital Group report.
FDA to avoid regulating most wearables, seeking to reduce device accessory regulation overall
21 January 2015
FirstWord Lists – The drugs that will shape 2015
21 January 2015
Which pharmaceutical products – both marketed and in the pipeline – will dictate industry news flow over the next 12 months?
Medical device, diagnostic venture investment at $2.7B, highest since 2008
20 January 2015
Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter
What's next for next-gen sequencing? Everything.
20 January 2015
More than a few presentations at the JP Morgan Healthcare conference this week sought to address the future of next-generation sequencing, particularly with the huge waves of related news. Foundation Medicine ($FMI) sold half its company to Roche ($RHHBY) for up to $1.2 billion and NantHealth is already being used in most cancer centers to guide treatment with a whopping $1.5 billion already spent to get it there and another $800 million raised in the last 6 months.
The 2015 biotech takeover target list includes some hot new players
20 January 2015
With the big multinationals like Merck ($MRK), Roche ($RHHBY), Pfizer ($PFE) and Johnson & Johnson ($JNJ) joining some of the most aggressive biotechs (think Shire) in roaming the planet in search of the right biotech targets to acquire, you can expect to see a steady stream of fresh speculation among analysts over which companies figure as the most likely buyout--and the next place to score some quick cash by investors.
New FDA quality office to grade manufacturing operations
20 January 2015
The FDA has shared details of plans for its Office of Pharmaceutical Quality (OPQ). Staffers plan to group drug production operations by category and release an average quality grade for each bucket, allowing manufacturers to see if they are outperforming their peers.
New Moscow site makes markers to identify cancer, HIV and then some
19 January 2015
Developers in Moscow have launched the production of medical markers to identify a range of serious diseases. They expect that a few years from now the new product may be delivered to every Russian clinic, the website of Vesti TV reported .
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024